nfcol.net Neurofibromatosis Clinical Reference · EN / ES

MEK1/2 Toxicity Monitoring & Adult Transition in NF1

Head-to-head SPRINT, KOMET, and ReNeu trial efficacy and toxicity matrix, organ-system safety thresholds for skin, LVEF, retina, and CPK, plus structured pediatric-to-adult neurofibromatosis transition protocols.

Updated 2026-11-18 · Synthesizing SPRINT, KOMET (Lancet 2025), ReNeu, & 2026 Meta-Analyses
Outpatient cardio-oncology workstation with an echocardiography probe, grayscale four-chamber cardiac ultrasound display, blood-draw tubes for CPK monitoring, and amber emollient bottle

1. Comparative Trial Efficacy & Toxicity Rates Across Ages

Oral MEK1/2 inhibitors reduce symptomatic inoperable NF1 plexiform neurofibromas in 41% to 70% of patients in single-arm studies and 20% versus 5% with placebo in randomized KOMET. Safe long-term therapy requires proactive dermatologic care, scheduled echocardiographic LVEF and retinal OCT checks, CPK triage, and structured pediatric-to-adult transition planning.

Selecting between selumetinib (Koselugo) and mirdametinib (Gomekli) requires looking beyond headline objective response rates (ORR, defined by REiNS criteria as a 20% or greater reduction in 3D volumetric MRI tumor volume). Age at initiation, trial design, and adverse-event distributions diverge sharply between pediatric cohorts and adult neurology clinics. In a 2026 PRISMA systematic review and meta-analysis of 9 clinical trials encompassing 528 patients across selumetinib, mirdametinib, trametinib, and binimetinib, pooled descriptive volumetric ORR was 53.7% (95% CI 40.5% to 66.6%), with higher shrinkage rates in children (62.9%) than in adults (40.8%, or 49.0% when excluding the randomized KOMET trial) (Damodharan & Tonsgard, PLoS One 2026).

Understanding why adult response rates appear lower in KOMET than in single-arm cohorts helps prevent premature treatment abandonment. KOMET randomized 145 symptomatic adults 1:1 to continuous oral selumetinib (25 mg/m² twice daily, n=71) or placebo (n=74) and assessed confirmed volumetric response strictly by Cycle 16; selumetinib achieved a statistically significant ORR of 19.7% (14/71, 95% CI 11.2% to 30.9%) versus 5.4% (4/74, 95% CI 1.5% to 13.3%) with placebo (p=0.011), with a median time to response of 3.7 months and a mean PAINS-pNF chronic pain score reduction of 2.0 points at Cycle 12 versus 1.3 points on placebo (Chen et al., The Lancet 2025; ClinicalTrials.gov NCT04924608). By contrast, the open-label Phase 2b ReNeu trial evaluated intermittent mirdametinib (2 mg/m² twice daily, max 4 mg BID, 21 days on and 7 days off) across up to 24 cycles in 114 patients, demonstrating confirmed volumetric ORR of 51.8% (95% CI 38.0% to 65.3%) in 56 children and 41.4% (95% CI 28.6% to 55.1%) in 58 adults (ClinicalTrials.gov NCT03962543; Hirbe et al., Frontiers in Oncology 2026). Clinicians also track investigational selective MEK1/2 agents such as tunlametinib, which achieved a 53.3% ORR (8/15 adults, median volume change -23.5%) in a 2026 adult Phase IIa study (Wang et al., Clinical Cancer Research 2026).

Trial Efficacy (ORR) vs Organ-Specific Adverse Event Incidence (%) Primary Registry Datasets (NCT04924608 / NCT03962543) KOMET Adult Selumetinib (n=71) ReNeu Adult Mirdametinib (n=58) ReNeu Pediatric Mirdametinib (n=56) 0% 20% 40% 60% 80% Confirmed Volumetric ORR 19.7% 41.4% 51.8% (SPRINT ped: 70.0%) Acneiform Dermatitis 59.2% 77.6% 42.9% Blood CPK Elevation 45.1% 13.8% 21.4% Paronychia (Nail Fold) 12.7% 1.7% 32.1% LVEF Reduction 7.0% 15.5% 26.8% Note: Cross-trial comparisons reflect distinct assessment cutoffs (KOMET Cycle 16 vs ReNeu 24-cycle) and non-randomized strata.
Figure 1. Quantitative comparison of confirmed 3D volumetric MRI response rates and core organ-system adverse events across KOMET randomized adult selumetinib (n=71), ReNeu adult mirdametinib (n=58), and ReNeu pediatric mirdametinib (n=56) cohorts.
Trial & Agent Cohort & Regimen Confirmed Volumetric ORR Key Dermatologic & GI Rates CPK, Cardiac & Ocular Signals
SPRINT Phase II
Selumetinib (NEJM 2020)
50 children (median age 10.2 yr; range 3.5 to 17.4 yr). 25 mg/m² BID continuous 28-day cycles 70.0% (35/50 PR; 28 durable ≥1 yr); 1-yr mean tumor pain reduction -2.0 points Most frequent AEs: nausea, vomiting, diarrhea, acneiform rash, and paronychia; 5/50 (10%) discontinued for toxicity Frequent asymptomatic blood CPK increase; scheduled serial LVEF echocardiograms & ophthalmic exams required
KOMET Phase III
Selumetinib (Lancet 2025)
145 adults randomized 1:1 (n=71 selumetinib vs n=74 placebo). 25 mg/m² BID continuous 19.7% (14/71) by Cycle 16 vs 5.4% (4/74) placebo (p=0.011); median onset 3.7 mo Acneiform dermatitis 59.2% (42/71); diarrhea 42.3%; nausea 25.4%; paronychia 12.7% (23.9% over extended BID) Blood CPK increased 45.1% (32/71 vs 5.4% placebo); LVEF decreased 7.0% (5/71); blurred vision 0% in RCT phase
ReNeu Pediatric
Mirdametinib (NCT03962543)
56 children (ages 2 to 17 yr). 2 mg/m² BID (max 4 mg BID), 21 days on / 7 days off 51.8% (95% CI 38.0% to 65.3%) across up to 24-month treatment phase Diarrhea 55.4%; acneiform dermatitis 42.9%; vomiting 39.3%; paronychia 32.1% (18/56) LVEF decreased 26.8% (15/56); CPK increased 21.4% (12/56); blurred vision 7.1% (4/56); RVO 0%
ReNeu Adult
Mirdametinib (NCT03962543)
58 adults (≥18 yr). 2 mg/m² BID (max 4 mg BID), 21 days on / 7 days off 41.4% (95% CI 28.6% to 55.1%) across up to 24-month treatment phase Acneiform dermatitis 77.6% (45/58); diarrhea 58.6%; nausea 51.7%; paronychia 1.7% (1/58) LVEF decreased 15.5% (9/58); CPK increased 13.8% (8/58); blurred vision 12.1% (7/58); RVO 1.7% (1/58)
Chinese Long-Term & Adult IIa
Selumetinib / Tunlametinib
NCT04590235 pediatric selumetinib (n=16, median 45 cycles); Tunlametinib adult IIa (n=15) 81.3% pediatric long-term (median -47.3% volume at Cycle 42); 53.3% tunlametinib adult IIa 75.0% pediatric TRAE rate (all Grade 1 to 2, 0% Grade ≥3 TRAEs in 16 children); 100% mild/moderate AEs on tunlametinib Long-term pediatric follow-up showed preserved growth velocity and reduced CALM pigmentation (Front Pharmacol 2026)

2. Organ-System Toxicity Protocols: Skin, Heart, Retina & CPK

Across real-world NF1 clinics, premature discontinuation rarely stems from true organ failure; it most often occurs when preventable Grade 1 to 2 mucocutaneous, gastrointestinal, or asymptomatic laboratory reactions trigger unguided dose holds. Proactive counseling and predefined escalation thresholds maintain dose intensity through Cycles 4 to 8, when measurable volumetric shrinkage typically consolidates.

Dermatologic Prophylaxis & Age-Divergent Cutaneous Care

Notice the striking age inversion in registry data: post-pubertal adolescents and adults experience markedly higher rates of follicular acneiform dermatitis (77.6% in ReNeu adults; 59.2% in KOMET adults vs 42.9% in ReNeu children), whereas pre-pubertal children develop nail-fold paronychia far more frequently (32.1% in ReNeu children vs 1.7% in ReNeu adults). Guidance published by the ReNeu Scientific Steering Committee and oncodermatology specialists (Hirbe et al., Frontiers in Oncology 2026) emphasizes pre-emptive barrier preservation starting on Cycle 1 Day 1 rather than waiting for pustular flares.

  • Day-1 Barrier & Photoprotection Kit: Apply thick, fragrance-free ceramide or petrolatum-based emollients twice daily to the trunk and face, switch to gentle non-soap cleansers, avoid alcohol-based acne scrubs or benzoyl peroxide (which worsen MEK-induced xerosis), and wear broad-spectrum SPF 30+ mineral sunscreen daily.
  • Acneiform Papulopustular Rash Escalation: For Grade 1 lesions (localized papules/pustules covering <10% body surface area without pain), initiate topical clindamycin 1% gel plus low-potency topical hydrocortisone 1% to 2.5% cream twice daily for 2 to 4 weeks. For Grade 2 flares (10% to 30% BSA or psychosocial distress), add oral tetracycline-class antibiotics (doxycycline 50 to 100 mg BID or minocycline in patients aged 8 years and older; avoid tetracyclines under age 8 due to permanent dental enamel staining) and consult dermatology before reducing MEK dose.
  • Paronychia & Nail-Fold Care: Instruct families to wear wide-toe-box breathable shoes, avoid aggressive cuticle trimming or ingrown-nail picking, and begin warm dilute white-vinegar (1:1 with water) or 0.05% chlorhexidine 15-minute soaks at the earliest periungual erythema, adding high-potency topical steroid ointment under occlusion or topical mupirocin if secondary bacterial colonization develops.

Cardiac LVEF, Ophthalmic OCT & CPK Laboratory Triage

Subclinical cardiac and laboratory changes require structured differentiation between benign pharmacodynamic signals and true organ toxicity:

Organ / Biomarker Mandatory Surveillance Cadence Asymptomatic Mild Signal (Continue) Hold, Confirm & Dose-Reduce Threshold
Cardiac LVEF (Echocardiogram) Baseline before Cycle 1, every 3 months during Year 1, then every 6 months (plus upon any dyspnea or peripheral edema) LVEF remains ≥50% (or above institutional LLN) with <10 percentage-point drop from baseline and zero heart-failure symptoms Asymptomatic LVEF drop ≥10% below baseline AND below LLN: hold MEK1/2 for up to 4 weeks; resume at 1 dose reduction if LVEF recovers. Permanent discontinuation for symptomatic cardiomyopathy
Retina (Dilated Exam + OCT) Baseline, 3 months, 6 months, then every 6 to 12 months; immediate urgent visit for floaters, flashes, or blurred vision Trace peripheral asymptomatic serous fluid without foveal involvement may be monitored closely in coordination with retina specialist Symptomatic retinal pigment epithelial detachment (RPED) or visual acuity drop: hold until OCT resolution, then resume at reduced dose. Permanent stop for retinal vein occlusion (RVO)
Serum CPK & Transaminases Baseline, prior to Cycle 2, and every 3 months (educate athletes against strenuous eccentric exercise 48 h prior to labs) Asymptomatic Grade 1 to 2 CPK elevation (≤5× ULN) without myalgia, dark urine, or creatinine rise: continue full dose and hydrate CPK >5× ULN or any elevation paired with myalgia/myoglobinuria: hold drug, check renal panel and urinalysis, rule out rhabdomyolysis, resume reduced dose after normalization
GI Tract & Electrolytes Symptom check at every cycle (Cycles 1 to 4 peak incidence: diarrhea 42% to 59%, nausea 25% to 52%) Grade 1 loose stools (<4/day above baseline): oral hydration, soluble fiber, and early loperamide titration Grade ≥2 persistent diarrhea (≥48 h despite loperamide) or refractory vomiting: brief hold, evaluate electrolytes, resume at reduced BSA tier
Immediate Drug-Hold Triggers Between Scheduled Visits

Patients and parents should pause MEK inhibitor dosing and contact their NF oncology or neurology team the same day if any of the following occur: new sudden blurred vision, central dark spots, or visual field loss (rule out RPED or RVO), unexplained shortness of breath on exertion, orthopnea, or ankle swelling (rule out LVEF decline), or severe muscle pain accompanied by dark tea-colored urine (rule out rhabdomyolysis).

3. Pediatric-to-Adult Transition & Adult Neurology Clinic Care

Historically, thousands of adolescents with NF1 fell out of specialist follow-up between ages 16 and 21 because pediatric neuro-oncology programs discharged them into general primary care without a receiving adult neurofibromatosis team. A 2026 systematic literature review of 53 adult NF1-PN studies demonstrated high adult disease morbidity, with pain affecting 32.0% to 38.4% of adults, surgery attempted in 69.5% of cohorts (carrying 13.0% to 30.0% postoperative complication rates), and an untreated median annual PN volume change of -3.7% to +8.3%, while finding zero published studies quantifying formal transition pathways (Mrugala et al., Neuro-Oncology Advances 2026).

Two 2026 clinical consensus frameworks now define best practices for bridging this gap: the Madrid multidisciplinary transition report (Salvador et al., Drugs in Context 2026) and the adult neurology clinic review (Schulte et al., Neurology: Clinical Practice 2026), complemented by lifespan age-integration guidance (Armstrong et al., Neuro-Oncology 2026). Adult patients transferring into adult neurology or sarcoma clinics while taking a MEK1/2 inhibitor require four specific adjustments:

  1. Age-Specific Toxicity & Dose Recalibration: Transitioning teenagers frequently shift from pediatric paronychia dominance to adult acneiform folliculitis, fatigue (29.3% in ReNeu adults vs 12.5% in children), and nausea (51.7% vs 26.8%). In patients switching from pediatric capsules to adult care, clinicians also verify BSA caps (mirdametinib caps at 4 mg BID; selumetinib caps at 50 mg BID for BSA ≥1.9 m²) and discuss whether an intermittent 21-days-on / 7-days-off regimen improves adherence during university or full-time work.
  2. Adult Comorbidity & Reproductive Counseling: Unlike young children, adults entering care require baseline blood pressure screening for renal artery stenosis or pheochromocytoma prior to procedural sedation, annual contrast breast MRI starting at age 30 for women (Chapter 7 Schedule), and strict teratogenicity counseling. Both selumetinib and mirdametinib can cause fetal harm; females of reproductive potential and male patients with fertile partners must use effective contraception throughout therapy and for the label-mandated washout period (at least 1 week after selumetinib; 6 weeks for females and 3 months for males after mirdametinib).
  3. Insurance & Prior-Authorization Continuity: Begin adult specialty pharmacy transfer and re-authorization 90 days before a patient ages off pediatric clinic rosters or parental health plans, supplying archived baseline 3D volumetric MRI comparisons, baseline pain/function scores, and current echocardiogram/OCT dates so uninterrupted MEK supply is preserved.
  4. Written Transfer Summary for the Receiving Adult Neurologist: Every graduating patient should carry a one-page clinical passport listing constitutional NF1 variant status, exact anatomical location and volumetric baseline of target plexiform tumors, prior MEK start date and best volumetric response, history of any dose reductions for LVEF or rash, and prior baseline whole-body STIR MRI dates.

4. Resistance Escape, MPNST Limits & Perioperative Holds

Both clinicians and families must recognize the hard biological ceiling of MEK1/2 inhibition: benign plexiform neurofibromas are driven predominantly by single-pathway RAS-ERK hyperactivation, whereas malignant peripheral nerve sheath tumors (MPNST) acquire secondary CDKN2A/B deletions and Polycomb Repressive Complex 2 (SUZ12/EED) chromatin loss that render MEK blockade ineffective (Cancers 2026 Resistance Review). Even rational dual-pathway blockade failed to clear malignant progression in the Phase II SARC031 trial of selumetinib (50 mg BID) plus the mTOR inhibitor sirolimus (4 mg daily) across 21 patients with unresectable or metastatic MPNST: clinical benefit occurred in only 1 of 7 patients in Stage 1 and 1 of 14 in Stage 2, with a median treatment duration of just 2 cycles (Kim et al., Clinical Cancer Research 2026).

Consequently, if a patient taking selumetinib or mirdametinib develops focal nodular enlargement out of proportion to the rest of the tumor, nocturnal pain waking them from sleep, new motor weakness, or stone-hard induration, do not escalate MEK dosage or switch between Koselugo and Gomekli. Hold the MEK inhibitor and immediately trigger the Chapter 6 MPNST Escalation Gate (18F-FDG PET/CT with SUVmax ≥3.5 and diffusion-weighted MRI with ADC mapping) to exclude premalignant ANNUBP or high-grade MPNST before proceeding to PET-targeted core biopsy. Similarly, when benign plexiform tumors shrink sufficiently under MEK blockade to permit planned surgical debulking or orthopedic spine stabilization, multidisciplinary boards typically coordinate a brief perioperative drug hold around wound healing windows to minimize bleeding or cutaneous healing complications.

Frequently Asked Clinical Questions

Why do adult NF1 plexiform neurofibroma response rates differ between KOMET and ReNeu?

KOMET was an international randomized placebo-controlled Phase 3 trial measuring confirmed volumetric response by Cycle 16 (20% with selumetinib versus 5% with placebo), whereas ReNeu was a single-arm Phase 2b trial evaluating mirdametinib across up to 24 cycles (41.4% adult objective response rate).

How should acneiform rash and paronychia be managed on Koselugo or Gomekli?

Oncology and dermatology consensus recommends daily fragrance-free emollients and broad-spectrum sunscreen from Day 1, topical clindamycin or low-potency corticosteroids for Grade 1 papulopustular rash, oral doxycycline or minocycline in patients aged 8 years and older for Grade 2 flares, and dilute antiseptic nail soaks for paronychia.

Should an asymptomatic creatine phosphokinase elevation stop MEK inhibitor therapy?

Usually no. Asymptomatic Grade 1 or Grade 2 creatine phosphokinase elevations are frequent on selumetinib and mirdametinib without muscle injury. Clinicians evaluate for myalgia, weakness, or dark urine and reserve dose interruption for symptomatic rhabdomyolysis or severe Grade 3 to 4 elevations.

Key Consensus Guidelines & Primary Sources

  1. Gross AM, Wolters PL, Dombi E, et al. Selumetinib in Children with Inoperable Plexiform Neurofibromas (SPRINT Phase II). New England Journal of Medicine. 2020;382(15):1430-1442. NEJM 2020 (PubMed 32187457).
  2. Chen AP, Coyne GO, Wolters PL, et al. Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study. The Lancet. 2025;405(10496):2217-2230. The Lancet 2025 (PubMed 40473450); ClinicalTrials.gov NCT04924608.
  3. SpringWorks Therapeutics / ReNeu Study Group. Mirdametinib (PD-0325901) in pediatric and adult patients with NF1-associated plexiform neurofibromas (ReNeu Phase 2b). ClinicalTrials.gov NCT03962543.
  4. Hirbe AC, Anadkat MJ, Boull CL, Moertel CL, et al. Managing skin-related adverse events during mirdametinib treatment for NF1-PNs: expert guidance from the ReNeu trial. Frontiers in Oncology. 2026;16:1826735. Frontiers in Oncology 2026 (PubMed 42827732).
  5. Damodharan S, Tonsgard J. Efficacy and safety of MEK inhibitors for NF1-associated symptomatic, inoperable plexiform neurofibromas: A systematic review and meta-analysis. PLoS One. 2026;21(10):e0359957. PLoS One 2026 (PubMed 42837360).
  6. Salvador H, Lassaletta A, Lopez-Gutierrez JC, Cucurull M, Blanco I. Standalone NF1: guiding the transition from paediatric to adult care. Drugs in Context. 2026;15. Drugs in Context 2026 (PubMed 42820191).
  7. Schulte J, Brown RM, Lala N, Murthy NK, Raju GP, Mitchell JA, Yohay K. Managing Plexiform Neurofibroma and Other Complications of Neurofibromatosis Type 1 in the Adult Neurology Clinic: A Review. Neurology: Clinical Practice. 2026;16(6):e200662. Neurology Clinical Practice 2026 (PubMed 42913451).
  8. Armstrong AE, Gross AM, Klesse LJ, et al. Neurofibromatosis type 1-plexiform neurofibromas: Integrating treatment across pediatric and adult populations. Neuro-Oncology. 2026;28(4):847-863. Neuro-Oncology 2026 (PubMed 41645458).
  9. Mrugala M, Adeyemi A, Johns J, Yang X, Wolkenstein P. Disease burden and unmet needs in adults with neurofibromatosis type 1 and plexiform neurofibromas: A systematic literature review. Neuro-Oncology Advances. 2026;8(1):vdaf269. Neuro-Oncology Advances 2026 (PubMed 41798680).
  10. Kim A, Ballman KV, Wolters PL, et al. SARC031: A Phase II Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST). Clinical Cancer Research. 2026;32(6):1068-1077. Clinical Cancer Research 2026 (PubMed 41504652).
  11. Wang Z, Huang J, Liu J, et al. Efficacy and Safety of Tunlametinib in Adults with Inoperable Neurofibromatosis Type 1-Associated Plexiform Neurofibromas: Phase IIa Trial and Biomarker Research. Clinical Cancer Research. 2026;32(10):1934-1945. Clinical Cancer Research 2026 (PubMed 41671075).
  12. Zhang X, Sui W, Zheng H, Chen J, Yuan X. Durable responses to long-term selumetinib in Chinese pediatric NF1 patients with inoperable plexiform neurofibromas. Frontiers in Pharmacology. 2026;17:1855171. Frontiers in Pharmacology 2026 (PubMed 42394972).